Leptomeningeal melanoma

Summary

Leptomeningeal melanoma (MONDO:0003761) is a cancer and 2 clinical trials. A subtype of malignant leptomeningeal tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	leptomeningeal melanoma
Mondo ID	MONDO:0003761
DOID	DOID:6085
NCIT	C5317
SNOMED CT	277530005
GARD	0023656
Anatomy (UBERON)	UBERON:0000391
Is cancer (heuristic)	yes

Also known as: leptomeningeal melanoma · leptomeninx melanoma · leptomeninx melanoma (disease) · malignant melanoma of meninges · melanoma (disease) of leptomeninx · melanoma of the leptomeninges · meningeal melanoma

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › tumor of meninges › meningioma › malignant leptomeningeal tumor › leptomeningeal melanoma

Related subtypes (1): leptomeningeal sarcoma

Subtypes (2): pediatric leptomeningeal melanoma, adult leptomeningeal melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07414979	PHASE1	NOT_YET_RECRUITING	Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
NCT05984108	Not specified	UNKNOWN	Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System